Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-12 09:59 am Purchase | 2026-03-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | STATE STREET CORP STT | 12,208,360 4.900% | 1,135,149 (+10.25%) | Filing History |
| 2026-04-29 5:02 pm Purchase | 2026-03-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | VANGUARD CAPITAL MANAGEMENT LLC | 12,961,172 5.160% | 12,961,172 (New Position) | Filing History |
| 2026-03-26 4:09 pm Sale | 2026-03-13 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | VANGUARD GROUP INC | 0 0.000% | -20,730,939 (Position Closed) | Filing History |
| 2026-02-12 2:17 pm Purchase | 2025-12-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | Flynn James E | 14,341,000 6.810% | 2,172,000 (+17.85%) | Filing History |
| 2026-02-09 06:19 am Purchase | 2025-12-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | STATE STREET CORP STT | 11,073,211 5.300% | 2,223,623 (+25.13%) | Filing History |
| 2025-11-12 8:27 pm Purchase | 2025-11-04 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | RA CAPITAL MANAGEMENT L.P. | 15,302,186 7.300% | 15,302,186 (New Position) | Filing History |
| 2025-09-19 12:23 pm Purchase | 2025-09-12 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | Flynn James E | 12,169,000 5.800% | 5,793,857 (+90.88%) | Filing History |
| 2025-05-15 09:31 am Sale | 2025-03-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | Avoro Capital Advisors LLC | 8,700,000 4.200% | -4,350,000 (-33.33%) | Filing History |
| 2025-04-17 09:35 am Sale | 2025-03-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | BlackRock, Inc. BLK | 17,483,490 8.400% | -3,558,982 (-16.91%) | Filing History |
| 2024-11-07 10:52 am Purchase | 2024-10-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | VANGUARD GROUP INC | 20,730,939 10.020% | 424,343 (+2.09%) | Filing History |
| 2024-11-07 10:25 am Unchanged | 2024-09-30 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | VANGUARD GROUP INC | 20,306,596 9.810% | 0 (Unchanged) | Filing History |
| 2024-11-04 11:18 am Purchase | 2024-09-30 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | VANGUARD GROUP INC | 20,306,596 9.810% | 2,542,876 (+14.31%) | Filing History |
| 2024-10-17 11:52 am Sale | 2024-09-30 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | STATE STREET CORP STT | 8,849,588 4.300% | -3,927,415 (-30.74%) | Filing History |
| 2024-09-10 12:09 pm Purchase | 2024-08-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | BlackRock, Inc. BLK | 21,042,472 10.200% | 2,361,102 (+12.64%) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | BAKER BROS. ADVISORS LP | 10,204,089 4.980% | -8,980,705 (-46.81%) | Filing History |
| 2024-02-14 09:02 am Purchase | 2023-12-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | Avoro Capital Advisors LLC | 13,050,000 6.400% | 13,050,000 (New Position) | Filing History |
| 2024-02-13 5:00 pm Purchase | 2023-12-29 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | VANGUARD GROUP INC | 17,763,720 8.670% | 3,559,325 (+25.06%) | Filing History |
| 2024-01-24 5:23 pm Purchase | 2023-12-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | BlackRock, Inc. BLK | 18,681,370 9.100% | 3,762,415 (+25.22%) | Filing History |
| 2024-01-24 1:06 pm Purchase | 2023-12-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | STATE STREET CORP STT | 12,777,003 6.240% | 1,650,142 (+14.83%) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | BAKER BROS. ADVISORS LP | 19,184,794 9.950% | 720,050 (+3.90%) | Filing History |